A comparative analysis of health technology assessment decision-making for cancer drugs in Germany and England. [PDF]
Front Public HealthHe J +6 more
europepmc +1 more source
Could Amnog Become Irrelevant in the 21st century? Potential Redundancies in The Amnog Process in the ERA of Curative Therapies [PDF]
Value in Health, 2016 openaire +1 more source
Evidence quality and uncertainties considered in appraisal documents of drugs for rare diseases in England and Germany: a data extraction protocol. [PDF]
BMJ OpenWiedmann L, Nolte E, Cairns J.
europepmc +1 more source
Price determinants and pricing policies concerning potentially innovative health technologies: a scoping review. [PDF]
Eur J Health EconXander NSH +11 more
europepmc +1 more source
Examining confidential wholesale margin estimates in European countries for the price negotiation of patented drugs in Germany: a statistical model. [PDF]
Health Econ RevAn der Heiden I +5 more
europepmc +1 more source
The role of financial distress as a patient-relevant endpoint in early benefit assessments for oncology drugs: a mixed-methods document analysis. [PDF]
Int J Technol Assess Health CarePauge S +3 more
europepmc +1 more source
DDD-costs have a strong influence on antibacterial drug prescription in Germany: a differentiated correlation analysis from 1985 to 2022. [PDF]
Naunyn Schmiedebergs Arch PharmacolBindel LJ, Seifert R.
europepmc +1 more source
Costs are a major driver of antibacterial drug prescriptions in Germany: market analysis from 1985 to 2022. [PDF]
Naunyn Schmiedebergs Arch PharmacolBindel LJ, Seifert R.
europepmc +1 more source
Impact of Systemic Delays for Patient Access to Oncology Drugs on Clinical, Economic, and Quality of Life Outcomes in Canada: A Call to Action. [PDF]
Curr OncolSehdev S, Gotfrit J, Elias M, Stein BD.
europepmc +1 more source